RFS Pharma LLC
Division of Cocrystal Pharma Inc.
Latest From RFS Pharma LLC
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.
BioLineRx has met a recent goal of adding an oncology asset to its pipeline and continued to fulfil its stated mission of filling the gap between basic research and late-stage development - especially among its Israeli colleagues - by licensing the worldwide rights to Biokine Therapeutics' BKT-140, now known as BL-8040.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Cocrystal Pharma Inc.
- Senior Management
William H Ollinger, VP, Fin.
Pascual Luz, VP, Medical Affairs
- Contact Info
RFS Pharma LLC
Phone: (404) 601-1430
1860 Montreal Rd.
Tucker, GA 30084
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.